Drugs / Danaparoid Sodium
last change Jun 2022 re-read 2 minutes ago

Danaparoid Sodium

targets SERPINC1 via activation

Developed for
heparin-induced thrombocytopenia
Investigated by
Aspen Global Incorporated

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) ORGARAN 2001-06-26 fda.gov
Approved US (FDA) ORGARAN 1996-12-24 fda.gov

Trials 1 · a red edge is where a trial was stopped

today
US approved 1996
NCT03809481 · Ph 3
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03809481 May 2019 → Jun 2022 heparin-induced thrombocytopenia Aspen Global Incorporated Terminated No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Danaparoid Sodium “Drug: Danaparoid SodiumNCT03809481
Known as Danaparoid ClinicalTrials.gov intervention name — accepted as the source's own label NCT03809481
Known as Danaparoide de sodio ChEMBL registry synonym — accepted as the source's own label CHEMBL1201534
Known as Danaparoide sodique ChEMBL registry synonym — accepted as the source's own label CHEMBL1201534
Known as ORG 10172 ChEMBL registry synonym — accepted as the source's own label CHEMBL1201534
Known as Orgaran ChEMBL registry synonym — accepted as the source's own label CHEMBL1201534
Known as Sodium danaparoid ChEMBL registry synonym — accepted as the source's own label CHEMBL1201534
Action Activate “Antithrombin-III activator” CHEMBL1201534
Action Inhibit inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation” NCT03809481
Route Intravenous “Subjects will receive danaparoid via IV infusion for at least 7 days then transition to a VKA.” NCT03809481
Target SERPINC1 “Antithrombin-III activator” CHEMBL1201534